KLRA

Kailera Therapeutics, Inc.

Healthcare · Biotechnology

11.00$ -1.2% vs. previous close Closing price · As of: Sep 29, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Income Statement KLRA
Line item	2025
Revenue	0.00
Research & Development	0.93
Selling, General & Administrative	0.42
Total Operating Expenses	1.34
Operating Income	-1.34
Pre-Tax Income	-1.26
Net Income	-1.26
EBITDA	-1.34

Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.